Verition Fund Management
KYMR icon

Verition Fund Management’s Kymera Therapeutics KYMR Stock Holding History

Verition Fund Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,319
Closed -$4.23M – 2980
2025
Q4 		$4.23M Buy
54,319
+22,848
+73% +$1.54M 0.02% 1002
2025
Q3 		$1.78M Buy
31,471
+22,987
+271% +$1.04M 0.01% 2076
2025
Q2 		$370K Sell
8,484
-21,406
-72% -$737K ﹤0.01% 3094
2025
Q1 		$818K Buy
29,890
+24,543
+459% +$895K ﹤0.01% 2270
2024
Q4 		$215K Buy
5,347
+212
+4% +$9.57K ﹤0.01% 2946
2024
Q3 		$243K Sell
5,135
-2,821
-35% -$125K ﹤0.01% 2766
2024
Q2 		$237K Buy
+7,956
New +$275K ﹤0.01% 2490

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Verition Fund Management's KYMR Position: Q1 2026 in Review

Verition Fund Management sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 54,319 shares — an estimated $4.23M sold.

Verition Fund Management first reported a position in KYMR in Q2 2024 and held it in 7 quarters. The position peaked at $4.23M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Verition Fund Management reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 54,319 Kymera Therapeutics shares in Q1 2026, an estimated $4.23M.
  • Verition Fund Management first reported a position in Kymera Therapeutics in Q2 2024 and held it in 7 quarters.
  • Verition Fund Management's Kymera Therapeutics position peaked at $4.23M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.